Angiogenic gene therapy for refractory angina

Expert Opinion on Biological Therapy

Volumn 16, Issue 3, 2016, Pages 303-315

  Rubanyi, Gabor M ^a  

^a Angionetics Inc   (United States)

Author keywords

Adenovirus; Angina pectoris; Angiogenesis; Arteriogenesis; Cell therapy; Clinical trial design; Coronary collaterals; Fibroblast growth factor; Gene therapy; Myocardial ischemia

Indexed keywords

ANGIOGENIC PROTEIN; FIBROBLAST GROWTH FACTOR; VASCULOTROPIN A;

ALTERNATIVE MEDICINE; ANGINA PECTORIS; ANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; CELL THERAPY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY COLLATERAL CIRCULATION; GENE TARGETING; HUMAN; REFRACTORY ANGINA; REVIEW; ADENOVIRIDAE; ANGIOGENESIS; BIOLOGICAL THERAPY; COLLATERAL CIRCULATION; GENE THERAPY; GENETICS; PROCEDURES; STEM CELL TRANSPLANTATION;

ADENOVIRIDAE; ANGINA PECTORIS; CELL- AND TISSUE-BASED THERAPY; COLLATERAL CIRCULATION; FIBROBLAST GROWTH FACTORS; GENETIC THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84957974673     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1122753     Document Type: Review

References (90)

1. Yla-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther. 2012; 20:1831-1832.
2. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2015 update. Circulation. 2015; 131: e29-e322.
3. Heart Disease Canada. Accessed online on September 7, 2015 at http://www.healthycanadians.gc.ca/diseases.
4. Daly CA, Clemens F, Lopez Sendon JL, et al. The clinical characteristics and investigations planned in patients with stable angina presenting cardiologists in Europe: from the Euro Heart Survey of Stable Angina. Eur Heart J. 2005; 26: 996-1010.
5. Peterson E. The burden of angina pectoris and its complications. Clin Cardiol. 2007; 30(S1):I10-15.
6. Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol. 1999; 84:598-600.
7. Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina. Report from the ESC Joint Study Group on the treatment of refractory angina. Eur Heart J. 2002; 23: 355-370.
8. Rubanyi GM Mechanistic, technical and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors. Mol Ther. 2013;21:725-738.
9. William F, Boden MD, Robert A, et al. Medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356:1503-1516.
10. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011; 109:428-436.
11. Kiernan TJ, Boilson BA, Sandhu GS, et al. Nonrevascularizable coronary artery disease following coronary artery bypass graft surgery: a populationbased study in Olmsted County, Minnesota. Corn Artery Dis. 2009; 20:106-111.
12. Isner JM. Angiogenesis and collateral formation. In: March KL, ed. Gene transfer in the cardiovascular system: experimental approaches and therapeutic implications. Boston, MA: Kluwer Academic Publishers; 1997:307-330.
13. Psaltis PJ, Simari RD. Cell therapy for refractory angina: time for more action. Stem Cell Res & Ther. 2011; 2:43-45.
14. Blatchley MR, Gerecht S. Acellular implantable and injectable hydrogels for vascular regeneration. Biomed Mater. 2015; 10: 1-13.
15. Zbinden R, Zbinden S, Meier P, et al. Coronary collateral flow in response to endurance exercise training. Eur J Cardiovasc Prev Rehabil 2007;14:250-257.
16. Gloekler S, Meier P, De Marchi SF, et al. Coronary collateral growth by external counterpulsation: a randomised controlled trial. Heart 2010;96:202-207.
17. Boodhwani M, Sellke FW. Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress. Antioxid Redox Signal.2009; 11:1945-1959.
18. Chilian WM, Penn MS, Pung YF, et al. Coronary collateral growth-back to the future. J Mol Cell Cardiol. 2012; 52: 905-911.
19. Seiler C, Fleisch M, Garachemani A, et al., Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol. 1998; 32: 1272-1279.
20. Heusch G, Guth BD, Seitelberger R, et al. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation. 1987; 75:482-490.
21. Lazarous DF, Scheinowitz M, Shou M, et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation. 1995; 91:145-153.
22. Schaper W, Flameng W, Winkler B, et al. Quantification of collateral resistance in acute and chronic experimental coronary occlusion in the dog. Circ Res. 1976; 39:371-377.
23. Seiler C. The human coronary collateral circulation. Eur J Clin Invest. 2010;40:465-476.
24. Jang WJ, Yang JH, Choi S-H, et al. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation. J Am Coll Cardiol Intv. 2015; 8:271-279.
25. Yetkin E, Topal E, Erguzel N, et al. Diabetes mellitus and female gender are the strongest predictors of poor collateral vessel development in patients with severe coronary artery stenosis. Angiogenesis. 2015; 18:201-207.
26. Billinger M, Kloos P, Eberli F, et al. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease. J Am Coll Cardiol. 2002;40:1545-1550.
27. Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation. 1991;83:739-746.
28. Steg PG, Kerner A, Mancini GB, et al. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial (OAT). Circulation. 2010;121:2724-2730.
29. Meier P, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation. 2007;116:975-983.
30. Meier P, Hemingway H, Lansky AJ, et al. The impact of the coronary collateral circulation on mortality: a metaanalysis. Eur Heart J. 2012;33:614-621.
31. Suárez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res. 2009; 104: 442-454.
32. Laham RJ, Rezae M, Post M, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos. 1999; 27:821-826.
33. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA. 1993; 90:1513-1517.
34. Awada HK, Johnson NR, Wang Y. Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction. J Contr Rel. 2015; 207:7-17.
35. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther. 2007;15:1233-1247.
36. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009;105:724-736.
37. Gaffney MM, Hynes SO, Barry F, et al. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol. 2007;152:175-188.
38. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002; 105:1291-1297.
39. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina (AGENT-2). J Am Coll Cardiol. 2003;42:1339-1347.
40. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007;50:1038-1046.
41. Kaski JC, Consuegra-Sanchez L. Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin Biol Ther. 2013; 13:1749-1753.
42. The ASPIRE trial protocol at the United States NIH website: ClinicalTrials.gov (Id: NCT01550614).
43. Fisher SA, Doree C, Brunskill SJ, et al. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLOS One. 2013; 8:e64669.
44. Losordo DW, Schatz RA, White CI, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double blind, randomized controlled study. Circulation.2007; 115: 3165-3172.
45. Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double blinded, active-controlled, unblended standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013; 165:854-861.
46. Musialek P, Mazurek A, Jarocha D, et al. Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf unlimited therapeutic agent: results from the Acute Myocardial Infarction First-In-Man Study. Post Kardiol Inter. 2015; 11:100-107.
47. Rubanyi GM. Identifying and overcoming obstacles in angiogenic gene therapy for myocardial ischemia. J Cardiovasc Pharmacol. 2014; 64:109-119.
48. Schaper W, DeBrabander M, Levi P. DNA-synthesis and mitoses in coronary collateral vessels of the dog. Circ Res. 1971;28:671-679.
49. Scheel KW, Williams SE. Hypertrophy and coronary and collateral vascularity in dogs with severe chronic anemia. Am J Physiol. 1985;249:H1031-H1037.
50. Chilian WM, Mass HJ, Williams SE, et al. Microvascular occlusions promote coronary collateral growth. Am J Physiol. 1990;258:H1103-H1111.
51. Van Den Wijngaard JPHM, Schulten H, Van Horssen P, et al. Porcine coronary collateral formation in the absence of a pressure gradient of ischemic border zone. Am J Physiol. 2011;300:H1930-H1937.
52. Semenza GL. Regulation of tissue perfusion in mammals by hypoxia-inducible factor 1. Exp Physiol. 2007; 92: 988-991.
53. Van Royen N, Piek JJ, Buschmann I, et al. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res. 2001; 49: 543-553.
54. Probst P, Zangl W, Pachinger O. Relation of coronary arterial occlusion pressure during percutaneous transluminal coronary angioplasty to presence of collaterals. Am J Cardiol. 1985; 55: 1264-1269.
55. Piek JJ, Van Liebergen RA, Koch KT, et al. Comparison of collateral vascular responses in the donor and recipient coronary artery during transient coronary occlusion assessed by intracoronary blood flow velocity analysis in patients. J Am Coll Cardiol. 1997; 29: 1528-1535.
56. Futterman LG, Lemberg L. Cardiac repair with autologous bone marrow stem cells. Am J Crit Care. 2004; 13:512-518.
57. Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003; 92:1098-1106.
58. Murakami M, Nguyen LT, Hatanaka K, et al. FGFdependent stimulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011;121:2668-2678.
59. Nissen LJ, Cao R, Hedlund E-M, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007;117:2766-2777.
60. Onimaru M, Yonemitsu Y, Tanii M, et al. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxiamediated downregulation in ischemic limbs. Circ Res. 2002;91:923-930.
61. Fujii T, Yonemitsu Y, Onimaru M, et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol. 2006;26:2483-2489.
62. Rissanen TT, Markkanen JE, Arve K, et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. Faseb J. 2000;17:100-112.
63. Gao MH, Lai NC, Hammond HK. Signal peptide increases the efficacy of angiogenic gene transfer for treatment of myocardial ischemia. Hum Gene Ther. 2005;16:1058-1064.
64. Giordano FJ, Ping PP, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2:534-539.
65. Crystal RG Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther. 2014 25:3-11
66. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest. 2004; 113:516-527.
67. Boekstegers P, Von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 2000; 7:232-240.
68. Sasano T, Kikuchi K, McDonald AD, et al. Targeted high efficiency, homogenous myocardial gene transfer. J Mol Cell Cardiol. 2007;42:954-961.
69. Lyons M, Onion D, Green NK, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006; 14:118-128.
70. Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113:1909-1918.
71. Greig JA, Buckley SM, Waddington SN, et al. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad)5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther. 2009;17:1683-1691.
72. Logeart D, Hatem S, Rucker-Martin C, et al. Highly efficient adenovirus mediated gene transfer to cardiac myocytes after single-pass coronary delivery. Hum Gene Ther. 2000;11:1015-1022.
73. Fechner H, Noutsias M, Tschoepe C, et al. Induction of Coxsackie-adenovirus receptor expression during myocardial tissue formation and remodeling. Circulation. 2003;107:876-882.
74. Roth DA, McKirnan MD, Canestrelli I, et al. Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus. Hum Gene Ther. 2006; 17: 230-238.
75. Gao MH, Lai NC, McKirnan MD, et al. Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor 4: report of preclinical data. Hum Gene Ther. 2004; 15:574-587.
76. Shi W, Schmarkey S, Jiang R, et al. Ischemia-reperfusion increases transfection efficiency of intracoronary adenovirus type 5 in pig heart in situ. Hum Gene Ther Methods. 2012;23:1-9.
77. Harris TR, Overholser KA, Collins JC. Tracer exchange in the normal and ischemic myocardium. Fed Proc. 1984;43:164-170.
78. Roth D, Lai N, Gao M, et al. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther. 2004;15:989-994.
79. Kloner RA. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res. 2006; 70:297-307.
80. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. An Expert Panel Summ Circ. 2000;102:e73-e86.
81. Argaud L, Rioufol G, Lievre M, et al. Preconditioning during coronary angioplasty: no influence of collateral perfusion or the size of the area at risk. Eur Heart J. 2004; 25:2019-2025.
82. Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. 2005; 95:1456-1459.
83. Hachamovitch R, Hayes SW, Friedman JD, et al. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol. 2005;45:722-729.
84. Boiten HJ, Van Der Sijde JN, Ruitinga PR, et al. Long-term prognostic value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography. J Nucl Cardiol. 2012; 19:907-913.
85. Berman DS, Kang X, Schisterman EF, et al. Serial changes on quantitative myocardial perfusion SPECT in patients undergoing revascularization or conservative therapy. J Nucl Cardiol. 2001; 8:428-437.
86. Boodhwani M, Sodha NR, Mieno S, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation. 2007; 116: I31-I37.
87. Boodhwani M, Nakai Y, Mieno S, et al. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg. 2006; 81:634-641.
88. Semenza GL. Vasculogenesis, angiogenesis and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem. 2007; 102:840-847.
89. Schaper W. Collateral circulation: past and present. Basic Res Cardiol. 2009;104:5-21.
90. Carmeliet P, Jain K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307